The move, if signed off on by the FDA, would expand eligibility to 28 million children in the U.S.
cleared its first regulatory hurdle Tuesday for use in young children, after a Food and Drug Administration advisory committee voted to recommend it for emergency use authorization for those ages 5 to 11.
Despite the vote in favor, deciding whether the benefits of vaccination for young kids outweigh potential risks appeared to weigh heavily on the advisors."This is a much tougher one, I think, than we had expected coming into it," said committee member Dr. Eric Rubin, editor-in-chief of the New England Journal of Medicine."The data show that the vaccine works and it’s pretty safe, ...
"I think the likelihood that this vaccine is going to be effective is pretty likely in the six to 11 year old age group," Meissner said."The issue is side effects or adverse events that might be occurring after the vaccines." To committee member Dr. Amanda Cohn, a chief medical officer at the Centers for Disease Control and Prevention, the benefits of vaccination were much clearer.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FDA advisory panel OKs Pfizer vaccine for kids 5 to 11A Covid vaccine for kids passed its first regulatory hurdle. A FDA panel voted to authorize the Pfizer Covid vaccine for children. The vote now goes to the FDA.
Baca lebih lajut »
FDA Says Pfizer Vaccine Benefits Outweigh Risks In Kids 5 To 11FDA Says Pfizer Vaccine Benefits Outweigh Risks In Kids 5 To 11 “Kids could be fully vaccinated by Christmas.”🎄
Baca lebih lajut »
Live updates of FDA meeting on Pfizer's Covid vaccines for kids ages 5 to 11The FDA's key advisors on vaccines meet today to discuss and vote on Pfizer's Covid vaccine for kids.
Baca lebih lajut »
FDA Advisers Back Pfizer’s COVID-19 Vaccine For Young Kids Ages 5-11U.S. health advisers have endorsed kid-size doses of Pfizer's COVID-19 vaccine for younger children.
Baca lebih lajut »